Evidence map›Paper›PMID 10935499›Full record

ArticleNeoplasia (New York, N.Y.)1999

Changes in vascularization of human breast cancer xenografts responding to antiestrogen therapy.

C A Kristensen, L M Hamberg, G J Hunter, S Roberge, D Kierstead, G L Wolf, R K Jain

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Noninvasive real-time imaging of apoptosis.Proceedings of the National Academy of Sciences of the United States of America · 2002
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

C A KristensenDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA. cak@dadlnet.dk
L M Hamberg
G J Hunter
S Roberge
D Kierstead
G L Wolf
R K Jain
Massachusetts General Hospital · USHarvard University · US

Funding

PATHOPHYSIOLOGY OF EXPERIMENTAL AND HUMAN TUMORSR35CA056591 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 1993 to 1999
–
NCI NIH HHS R35-CA-56591
6 · The paper itself

Abstract

To elucidate the previously suggested vascular effect(s) of antiestrogen therapy, we studied the effect of estrogen withdrawal and tamoxifen on 1) vascular resistance, 2) glucose and oxygen consumption, and 3) vascular density in a perfused breast cancer line (ZR75-1). Furthermore, we examined ZR75-1 tumors by functional CT-scanning (fCT) to determine changes in parameters related to tumor capillary transfer constants and vascular volume fraction in response to antiestrogenic manipulations. The vascular resistance decreased significantly from 42.7 to 20.8 mmHg x min x g x ml(-1) (P< .03) on day 9 after estrogen withdrawal, but not after 9 days of tamoxifen treatment. The estrogen-depleted tumors were significantly smaller than controls on day 9. There was no difference in nutrient consumption or vascular density in any of the experimental groups compared to controls. fCT showed an increase (P < .03) in vascular volume fraction during tumor growth, and this parameter was significantly lower after estrogen withdrawal when compared to controls (P < .05). Vascular resistance correlated with tumor size (R = 0.7, P < .0001), indicating that vascular resistance increases during tumor growth. The changes in vascular parameters after estrogen withdrawal indicate a vascular remodeling effect. This inhibition of vascular development by hormone deprivation may have important implications for future planning of multimodal treatment regimens.

Indexed as

AnimalsEndothelial Growth FactorsEstrogen Receptor ModulatorsFemaleFibroblast Growth Factor 2HumansInfantLymphokinesMammary Neoplasms, ExperimentalMiceMice, NudeNeoplasm TransplantationNeovascularization, PathologicTamoxifenTransplantation, HeterologousTumor Cells, CulturedEndothelial Growth FactorsEstrogen Receptor ModulatorsFibroblast Growth Factor 2LymphokinesTamoxifenVascular Endothelial Growth Factor AVascular Endothelial Growth Factors

Identifiers

PMID10935499
PMCPMC1508121
OpenAlexW2055189600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.